Currently, there are 33.56M common shares owned by the public and among those 32.43M shares have been available to trade.
The company’s stock has a 5-day price change of -5.82% and -58.27% over the past three months. TMDX shares are trading -21.60% year to date (YTD), with the 12-month market performance down to -21.26% lower. It has a 12-month low price of $59.72 and touched a high of $177.37 over the same period. TMDX has an average intraday trading volume of 1.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.15%, -26.11%, and -47.00% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Transmedics Group Inc (NASDAQ: TMDX) shares accounts for 109.83% of the company’s 33.56M shares outstanding.
It has a market capitalization of $2.08B and a beta (3y monthly) value of 2.10. The stock’s trailing 12-month PE ratio is 66.30, while the earnings-per-share (ttm) stands at $0.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.03% over the week and 5.84% over the month.
Earnings per share for the fiscal year are expected to increase by 226.39%, and 49.80% over the next financial year.
Looking at the support for the TMDX, a number of firms have released research notes about the stock. JP Morgan stated their Neutral rating for the stock in a research note on December 17, 2024, with the firm’s price target at $116-$75. Oppenheimer was of a view on October 29, 2024 that the stock is Outperform, while Needham gave the stock Buy rating on October 29, 2024, issuing a price target of $208- $109. Robert W. Baird on their part issued Outperform rating on September 24, 2024.
